Phase I trial of concurrent taxotere with radiation therapy and hormonal therapy for clinically localized high risk prostate cancer.

Trial Profile

Phase I trial of concurrent taxotere with radiation therapy and hormonal therapy for clinically localized high risk prostate cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Docetaxel (Primary) ; Bicalutamide; Goserelin; Leuprorelin
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Mar 2017 Planned End Date changed from 1 Jan 2011 to 1 Dec 2017.
    • 28 Dec 2015 Planned primary completion date changed from 1 Dec 2012 to 1 Jan 2011, as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top